Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Add filters

Year range
Medical Principles and Practice. 2017; 26 (6): 535-541
in English | IMEMR | ID: emr-197080


Objective: Jo determine the effect of supplementation with n-3 polyunsaturated fatty acids (PUFAs) on circulatory resis-tin and monocyte chemoattractant protein 1 [MCP-1] levels in type 2 diabetes mellitus [T2DM] patients

Subjects and Methods: This was a 10-week, placebo-controlled, double-blind, randomized trial of n-3 PUFAs [2,700 mg/day] versus placebo [soft gels containing 900 mg of edible paraffin]. Forty-four T2DM patients were supplemented with n-3 PUFAs and another 44 patients received placebo (3 patients discontinued the trial]. Serum resistin, MCP-1, and the lipid profile were measured before and after supplementation. The adi-ponectin-resistin index [1 + Iog[10] [resistin] - Iog10 [adiponec-tin]] and atherogenic index [Iog[10] triglyceride/high-density lipoprotein cholesterol] of plasma [an indicator of cardiovascular complications] were assessed. The independent Student t test was used to assess the differences between the supplement and placebo groups and the paired f test to analyze the before/after changes

Results: In this study, n-3 PUFAs reduced serum MCP-1 levels [from 260.5 to 230.5 pg/ ml_;p = 0.002], but they remained unchanged in the placebo group, n-3 PUFAs could not decrease serum resistin levels. The adiponectin-resistin index was significantly reduced after supplementation with n-3 PUFAs when compared to theplacebo. The atherogenic index was also significantly improved after supplementation with n-3 PUFAs [from 1.459 to 1.412; p = 0.006]

Conclusions: The MCP-1 levels and lipid profile were improved after supplementation with n-3 PUFAs, but resistin serum levels were not changed. Hence, the anti-inflammatory effects of n-3 PUFAs might be mediated by targeting MCP-1